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Copyright © 2009 JCBN Summary The purpose of this study was to examine the effects of γ-aminobutyric acid
(GABA) in fermented drinking water prepared from sodium glutamate, vinegar, and dried
bonito (FDWG) compared with placebo [vinegar and dried bonito without GABA (FDW)] and
its safety in normotensive and mildly or moderately hypertensive volunteers. A double-blind,
placebo-controlled, randomized study was conducted involving volunteers with normal
(group-N) and mildly or moderately high (group-H) blood pressure (BP). After a pretreatment
period of 2 weeks (weeks –2), the subjects received FDWG or FDW for 12 weeks followed by
4 weeks of no intake (weeks 16). In group-H, both FDWG and FDW significantly decreased
systolic (SBP, −7.6 ± 4.0 and −5.5 ± 1.5 mmHg,  p<0.05, respectively) and diastolic (DBP,
−10.6 ± 4.0 and −7.6 ± 1.7 mmHg, p<0.01, respectively) BP compared to the baseline (0-week)
value at 12 weeks, respectively. There were no abnormal changes in hematological or blood
chemistry variables, urinalysis, heart rate, or body weight in the study groups. These findings
indicated that vinegar and dried bonito with or without GABA might have an effect on BP in
mildly or moderately hypertensive patients.
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Introduction
Hypertension is considered a major risk factor for the
progression of cerebrovascular and cardiovascular disorders.
The development of hypertension is caused by several
factors, including poor dietary and lifestyle habits. It isH. Tanaka et al.
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essential in mild or moderate hypertension for patients to
receive dietary therapy before beginning a course of medica-
tion [1].
The blood pressure (BP)-lowering effect of vinegar and
peptides from dried bonito has been shown in earlier reports
[2–4]. γ-Aminobutyric acid (GABA) is an amino acid that is
widely distributed in mammals, crustacea, microorganisms,
and many plants such as tea [5] and radish greens [6], as well
as mushrooms [7]. It is well-known that GABA is one of the
major inhibitory neurotransmitters and is present at a high
concentration in the central nervous system [8], but it also
exists in peripheral tissues [9]. Several animal experiments
have demonstrated the hypotensive effect of GABA [10–12].
Furthermore, the safety and hypotensive actions of some
food products containing GABA were shown in hyper-
tensive patients [13–15]. Therefore, the hypotensive effect
of drinking water containing vinegar and dried bonito with
may be stronger than that without GABA. However, the
overall impact of the food products containing GABA on BP
remains unclear.
Fermented drinking water containing GABA is prepared
from sodium glutamate, vinegar, and dried bonito (FDWG),
and GABA is transformed from sodium glutamate by
decarboxylase with the use of lactobacilli [16]. We have
performed preliminary experiments in rats using FDWG at
varying concentrations. As a result, there were problems in
regarding the predictability of the hypotensive effect, such
as transient hypotension or rebound hypertension at a high
concentration of GABA (600 mg/90 ml) (data not shown).
The above experiments were also conducted in humans,
showing that there were no problems at a low concentration
of GABA (200 mg/90 ml or less) for a short period (data
not shown). The BP-lowering effect of fermented milk
containing GABA at a concentration of 10–12 mg/100 ml
has also been reported by Inoue et al. [15]. We have chosen
FDWG at a concentration of 70 mg/90 ml (approximately
35% of 200 mg of GABA), which would be expected to
have a greater effect on BP than fermented milk containing
GABA (approximately 7-fold higher than that in the above
study [15]) and higher-level safety.
Thus, the purpose of this study was to examine the effects
of GABA in FDWG, compared with drinking water con-
taining vinegar and dried bonito without GABA (FDW),
and its safety in normotensive and mildly or moderately
hypertensive volunteers.
Materials and Methods
Subjects
The study population comprised 15 subjects with a
normal BP and 21 with mild or moderate hypertension
[systolic BP (SBP) is from 130 to 159 mmHg, and diastolic
BP (DBP) is from 85 to 99 mmHg] (JSH2004 grade) [1].
The criteria for patient selection were: being aged between
20 and 65 years; having no history of antihypertensive
medication; and having no other abnormal symptoms,
diagnostic opinions, hematological or blood chemistry
variables, or physical exam results. The criteria for subject
exclusion were: those with food allergies; those who took
medicine within seven days of the start of the study; those
medicated with other novel drugs within four months of the
start of the study; those requiring emergent antihypertensive
therapy; those with symptoms of cerebrovascular disorder,
heart failure and/or a previous history of myocardial infarc-
tion, atrial fibrillation and/or serious arrhythmia, renal
dysfunction (a serum creatinine level of more than 2.0 mg/
dl), severe liver disorder, diabetes, anemia (a hemoglobin
concentration of less than 9.5 g/dl); and those pregnant or
lactating. Subjects provided written informed consent
before participation. This study was approved by the ethics
committee of the Bio Research Center of Niigata City in
Japan.
Study protocol
This study was carried out using a placebo-controlled,
double-blind design and consisted of a two-week pre-
observation term (weeks –2) and a 12-week daily-intake
phase, which was followed by 4 weeks with no intake
(weeks 16) [13]. Subjects were classified into those with a
normal BP (group-N) and those with moderate or mild
hypertension (group-H) according to JSH2004 on 2 weeks
before the first intake. Each group was randomly split into
two subgroups by investigator. One subgroup of subjects
took 90 ml (one bottle) of FDWG daily for 12 weeks. The
other subgroup took FDW as a placebo. We measured the BP
and heart rate (HR) of seated subjects at weeks −2, 0, 2, 4, 8,
10, 12, 14, and 16. After BP measurement, we obtained
blood and urine samples for the assessment of hematological
and blood chemistry variables and urinalysis.
Test products
FDWG was prepared by Yasuda Yogurt Co., Ltd. (Niigata
Japan), and the method of preparation was as follows: dried
bonito powder was added to a mixture of liquid sugar from
rice and water, and, after decoction and cooling, protease
treatment was performed. Then, sodium glutamate and a
culture of lactic acid bacteria were added to the above
solution and fermented. The resultant preparation was
heated, sterilized, and filtered. Water, liquid sugar from
rice, vinegar, and malic acid were added to the above
solution; thus, FDWG was prepared. Ninety ml of FDWG
contains 2.07 g of vinegar, 0.15 g of dried bonito, and 70 mg
of GABA. FDW (the placebo not containing GABA) was
obtained by performing the same operation without adding
sodium glutamate. Ninety ml of FDW contains 2.07 g of
vinegar and 0.15 g of dried bonito, in which GABA wasThe Effects of GABA, Vinegar and Dried Bonito
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undetectable. The doses of vinegar and dried bonito used in
the study were determined considering earlier reports [3, 17],
each ingredients in FDWG which would be expected to
have hypotensive effect, and taste of test drinks.
Measurements
BP and HR were measured between 9:00 and 10:00 a.m.
at the Niigata Association of Occupational Health, Inc. BP
measurements were performed using a mercury sphygmo-
manometer while the subjects were seated after they had
rested for 15 min. Hematological and blood chemistry
variables were measured, and urinalysis was performed at
the laboratory of SRL Corporation in Japan. The GABA
concentration in FDWG and FDW was measured using ion-
exchange chromatography (Shimadzu Corporation, Japan)
and postcolumn fluorometric detection.
Statistical analysis
Data are presented as the mean ± standard error of the
mean. Analysis of variance and paired t tests were used to
analyze changes between the postintake and baseline levels
[18]. Differences between the FDWG- and FDW-intake
values were analyzed using unpaired t tests, which were also
employed to compare group-N with group-H. Significance
was established at p<0.05.
Results
Subject characteristics and side effects
All 36 subjects completed the study. Table 1 presents the
baseline demographics of all subjects. None of the subjects
developed any side effects during the study.
Blood pressure
In group-H, the time-courses of the SBP and DBP during
the two weeks of the preobservation, 12-week daily intake,
and the 4 weeks of the postintake observation term without
ingestion are shown in Fig. 1a. Both FDWG and FDW
lowered SBP and DBP modestly. A significant decrease
in SBP was noted from 10 weeks onwards in the FDWG
subgroup (−6.8 ± 3.3 mmHg,  p<0.05) and in the FDW
subgroup (−4.7 ± 2.0 mmHg,  p<0.05). DBP was signifi-
cantly decreased at 6, 10, 12, 14, and 16 weeks in the FDWG
subgroup (−9.6 ± 3.7 mmHg,  p<0.05;  −11.2 ± 4.0 mmHg,
p<0.05;  −10.6 ± 4.0 mmHg,  p<0.05;  −8.8 ± 2.8 mmHg,
p<0.01; and −10.4 ± 3.6 mmHg, p<0.01, respectively) and
at 4, 8, 10, 12, 14, and 16 weeks in the FDW subgroup
(−4.2 ± 1.8 mmHg,  p<0.05;  −5.6 ± 1.1 mmHg,  p<0.01;
−6.0 ± 1.8 mmHg,  p<0.01;  −7.6 ± 1.7 mmHg,  p<0.01;
−7.8 ± 1.5 mmHg, p<0.01; and −8.7 ± 0.9 mmHg, p<0.01,
respectively). The changes in SBP and DBP from the
baseline values after FDWG or FDW ingestion are shown
in Fig. 1b and 1c, respectively. The changes in SBP in the
FDWG subgroup tended to be lower than those in the FDW
subgroup at 8, 10, 12, and 14 weeks, and the decreases of
DBP in the FDWG subgroup tended to be lower than those
in the FDW subgroup at 6, 10, and 12 weeks, between which
there were no significant differences. Two weeks after test-
solution ingestion had stopped (14 weeks), SBP continued
decreasing in both the FDWG and FDW subgroups. At 4
weeks after test-solution ingestion had stopped (16 weeks),
SBP was increased but remained lower than the baseline
level in both the FDWG and FDW subgroups.
No significant decreases of SBP and DBP in group-N
were confirmed during FDWG or FDW ingestion (Figs. 2a,
b, and 3c).
Fig. 3 presents a comparison between group-N and group-
Table 1. Baseline clinical demographics of the four study groups
The FDWG subgroup did not differ significantly (p<0.05; unpaired t test) with respect to any characteristic compared with the
FDW subgroup in group-N and group-H. Where appropriate, data are presented as the mean ± standard error of the mean for the 8
subjects who received FDWG or the 7 subjects who received FDW in group-N, and the 10 subjects who received FDWG or the 11
subjects who received FDW in group-H. FDWG: fermented drinking water containing vinegar and dried bonito with GABA. FDW:
fermented drinking water containing vinegar and dried bonito without GABA.
Group-N Group-H
FDWG FDW FDWG FDW
Number of subjects 8 7 10 11
Men/women 7/1 3/4 5/5 10/1
Age (year) 45.1 ± 3.3 49.3 ± 10.5 45.7 ± 9.8 46.9 ± 3.2
Body weight (kg) 65.3 ± 8.0 66.7 ± 3.9 62.2 ± 5.3 62.5 ± 9.5
Height (cm) 167.9 ± 2.8 161.3 ± 3.6 165.7 ± 3.7 168.5 ± 1.9
Body mass index (kg/m2) 23.1 ± 0.7 22.3 ± 1.1 25.5 ± 0.9 21.9 ± 0.7
Systolic blood pressure (mmHg) 116.0 ± 2.8 115.7 ± 3.4 136.0 ± 1.9 130.2 ± 1.4
Diastolic blood pressure (mmHg) 76.0 ± 1.6 74.9 ± 2.5 92.2 ± 2.3 89.3 ± 2.4
Heart rate (beats/min) 68.0 ± 4.5 62.6 ± 1.2 66.9 ± 2.7 68.7 ± 3.7H. Tanaka et al.
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H regarding changes in SBP and DBP from baseline levels
after the intake of FDWG. SBP was significantly decreased
at 2 and 14 weeks (all p<0.05) in group-H compared with
group-N. DBP was significantly decreased at 2, 6, 8, 10, 12,
14, and 16 weeks (all p<0.05) in group-H compared with
group-N.
In all subjects (group-N + group-H), SBP was significantly
decreased from 8 weeks after FDWG intake (−4.0 ± 1.9
mmHg,  p<0.05) and from 12 weeks after FDW intake
(−4.4 ± 2.1 mmHg, p<0.05) compared to the 0-week value.
DBP was significantly decreased from 10 weeks in the
FDWG subgroup (−6.4 ± 2.7 mmHg, p<0.05) and from 8
weeks in the FDW subgroup (−3.0 ± 1.3 mmHg,  p<0.05)
compared to the 0-week value.
Heart rate, body weight, and body mass index
HR did not change significantly in any group. The base-
line HR was 68.0 ± 4.5 beats/min in group-N and 66.9 ±
2.7 beats/min in group-H before the intake of FDWG, and
62.6 ± 1.2 beats/min in group-N and 68.7 ± 3.7 beats/min
in group-H before the intake of FDW. After 12 weeks of
FDWG intake, HR was 65.0 ± 2.9 beats/min in group-N
and 67.2 ± 2.0 beats/min in group-H. After 12 weeks of
FDW intake, HR was 64.3 ± 1.7 beats/min in group-N and
66.4 ± 2.1 beats/min in group-H.
No significant change in body weight or the body mass
index was seen until FDWG or FDW intake in all subjects.
Hematological and blood chemistry variables, and urinalysis
Table 2 presents the results of hematology, blood
chemistry studies, and urinalysis before and after intake of
the test solution in all subjects. The 12-week intake of
FDWG significantly increased the chloride value and
decreased the levels of aspartate aminotransferase, γ-
glutamyl transpeptidase, total protein, lactate dehydrogenase,
and blood glucose compared to the first day of intake. In
the FDW group, chloride was significantly increased and
the hematocrit, red blood cells, total protein, albumin, and
blood glucose were significantly decreased after 12 weeks
compared to the first day of intake. These significant
changes remained within the normal ranges. The total
cholesterol levels were decreased from 192.2 ± 7.0 mg/dl to
183.9 ± 5.8 mg/dl in the FDWG subgroup and from
210.1 ± 8.3 mg/dl to 199.8 ± 6.5 mg/dl in the FDW sub-
Fig. 1. Time course of blood pressure (a) during the preobservation term, the intake period of FDWG (n = 10, closed circles) or FDW
(n = 11, open circles), and after finishing intake in group-H, and changes (relative to baseline values) in systolic (SBP) (b) and
diastolic (DBP) (c) blood pressure after the intake of FDWG or FDW. Each point represents the mean ± standard error. *p<0.05
and ** p<0.01 (paired t test) compared to the 0-week value.The Effects of GABA, Vinegar and Dried Bonito
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group, although these changes were not significant. There
were no significant differences between the FDWG and
FDW subgroups at 12 weeks.
The pH of urine was significantly decreased in the FDWG
subgroup after 12 weeks compared to the first day of intake.
However, these changes were within the normal range.
There were no abnormal findings regarding the levels of
protein in urine, urinary sugar, or urobilinogen in urine.
Discussion
BP reduction is effective in preventing stroke and other
vascular events, including heart failure [19–21]. The
purpose of this study was to examine the effects of GABA in
FDWG and its safety. In this study, 90 ml of FDWG taken
daily for 12 weeks lowered SBP and DBP compared to the
0-week value in mildly hypertensive patients without
affecting HR, but FDW (vinegar and dried bonito without
GABA) also exhibited these effects. Several constituents
of FDWG and FDW have been reported to lower BP. A
positive association between vinegar and BP has been
demonstrated [2–3]. It has also been reported that the
ingestion of peptides from dried bonito decreases BP in
spontaneously hypertensive rats [4]. Our previous study
showed that only an improvement in lifestyle habits had no
effect on BP reduction over 12 weeks (data not shown). The
BP-lowering effect of FDW was due to the presence of
vinegar and peptides in dried bonito. Our study clarified that
FDWG intake tended to be slightly more effective against
lowering BP than FDW intake, but the effects were not
significantly different. An additional study with a large
number of volunteers is needed to clarify the effects of
GABA on BP in the future.
Kajimoto et al. reported the hypotensive effect of drink
containing 15 g/100 ml of vinegar [3]. Kawasaki et al.
reported the antihypertensive effect of vegetable drink with
500 mg/195 ml of peptide derived from sardine protein [17].
We have chosen vinegar at a concentration of 2.07 g/90 ml
(15% of above report) because of 1) considering other
ingredients in FDWG which would be expected to have a
hypotensive effect and 2) considering taste of test drinks.
For similar reason, we have chosen dried bonito at a
concentration of 0.15 g/90 ml (60% of above report). The
concentration of GABA in FDWG was determined 70 mg/
Fig. 2. Time course of blood pressure (a) during the preobservation term, the intake period of FDWG (n = 8, closed squares) or FDW
(n = 7, open squares), and after finishing intake in group-N, and changes (relative to baseline values) in systolic (SBP) (b) and
diastolic (DBP) (c) blood pressure after the intake of FDWG or FDW. Each point represents the mean ± standard error. *p<0.05
(paired t test) compared to the 0-week value.H. Tanaka et al.
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90 ml, which would be expected to have a greater effect on
BP than fermented milk containing GABA (approximately
7-fold higher than that in the above study [15]). Therefore
we predicted that serum GABA concentration which had
not measured in this study might be increased by FDWG
intake, because Inoue et al. reported the hypotensive effect
of GABA at much less dose than we used [15]. However
there were no significant differences between FDWG and
FDW in group-H. Inoue et al. reported the hypotensive
effect of GABA in hypertensives (average of baseline SBP
was 155.1 ± 2.8 mmHg) [15]. One of the causes why there
were no significant differences between FDWG and FDW
in group-H might be due to the average baseline of SBP in
group-H in this study (136.0 ± 1.9 mmHg) which was lower
than above study [15].
Kajimoto et al. reported that the effect of GABA on BP
change was greater in hypertensive than in mildly hyper-
tensive patients [13]. This report was confirmed by our
results that no significant changes of BP were observed
during the intake of FDWG in normotensive subjects. The
BP remained below the baseline level for 4 weeks after
ceasing FDWG or FDW intake. The maintenance of a
decreased BP after the discontinuation of the long-term
administration of antihypertensive substances such as
peptide [22] and GABA [14] has been observed in humans.
The present results are in agreement with those of previous
studies [14, 22], which may indicate the safety of FDWG.
Indeed, there was no rebound phenomenon or excessive
hypotension after the discontinuation of FDWG in this study.
Regarding hematological and blood chemistry variables,
the total cholesterol values had fallen from the baseline
value after 12 weeks in both FDWG and FDW subgroups in
all subjects, but these changes were non-significant in this
small-scale study (n = 36). Blood glucose was significantly
decreased after 12 weeks in the FDWG and FDW subgroups
in all subjects. It has been reported that a drink containing
vinegar was beneficial in reducing serum total cholesterol
and blood glucose levels in humans [23,  24]. This was
comparable with our results.
In this study, no marked changes were observed in any of
the hematologic or clinical chemistry indexes measured.
Additionally, no other side effects were demonstrated in
any of the subjects. Because FDWG exhibited no effects on
serum cholesterol, blood glucose, or triacylglycerol concen-
trations, which were seen with diuretic and β-blockers
[25–28], vinegar, dried bonito and GABA might be safe for
patients with hypertension accompanied by hyperlipemia or
diabetes.
Study limitations
One potential limitation of this study could be the fact
that the BP decreased markedly in the FDW subgroup,
complicating the interpretation of the findings. The next
limitation is the weak statistical power due to the small
sample size, through which we could not effectively evaluate
BP attenuation or GABA safety. Moreover, the average
value of BP between FDWG and FDW subgroup on baseline
was not equivalent because of random grouping. Each group
should split into two subgroups considering the equability of
average values of BP. Additionally, measuring the plasma
GABA or plasma catecholamine concentrations would have
possibly been a valuable addition to the study. Also, it would
have been interesting to measure the growth hormone level,
since its regulation by GABA supplementation remains
controversial.
Conclusions
The results of the present study suggest that vinegar and
dried bonito with or without GABA might exhibit a BP-
lowering effect in mildly hypertensive patients.
Fig. 3. Changes (relative to baseline values) in systolic (SBP)
(a) and diastolic (DBP) (b) blood pressure after the
intake of FDWG in group-N (n = 8, squares) and group-
H (n = 10, circles). Each point represents the mean ±
standard error. *p<0.05 (paired t test) compared to the
week-matched value in group-N.The Effects of GABA, Vinegar and Dried Bonito
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Abbreviations
BP, Blood pressure; GABA, γ-Aminobutyric acid; FDWG,
Fermented drinking water containing vinegar and dried
bonito with GABA; FDW, Fermented drinking water
Table 2. Results of hematology, blood chemistry, and urinalysis before (week 0) and after (week 12) the intake of fermented drinking
water containing vinegar and dried bonito with (FDWG) or without (FDW) GABA.
Where appropriate, data are presented as the mean ± standard error of the mean for the 18 subjects who received FDWG or the 18 subjects
who received FDW. The FDWG subgroup did not differ significantly (p<0.05; unpaired t test) with respect to any characteristic compared
with the FDW subgroup. *p<0.05 (paired t test) compared to the 0-week value. **p<0.01 (paired t test) compared to the 0-week value.
FDWG subgroup FDW subgroup
Before After Before After
Hematology
Red blood cells (×104/μl) 474.4 ± 7.9 464.2 ± 9.8 464.7 ± 10.3 457.0 ± 11.6*
White blood cells (/μl) 5244.4 ± 336.8 5222.2 ± 369.6 5666.7 ± 258.2 5672.0 ± 260.6
Platelets (×104/μl) 22.9 ± 1.2 22.0 ± 1.1 25.0 ± 1.4 25.1 ± 1.3
Hemoglobin (g/dl) 14.1 ± 0.3 13.9 ± 0.3 14.4 ± 0.3 14.2 ± 0.3
Hematocrit (%) 42.8 ± 0.7 42.1 ± 0.8 42.8 ± 0.7 42.0 ± 0.9**
Blood chemistry variables
Aspartate aminotransferase (IU/l) 22.9 ± 1.3 20.6 ± 0.9* 20.7 ± 0.9 21.9 ± 1.0
Alanine aminotransferase (IU/l) 21.6 ± 2.7 18.4 ± 1.6 21.8 ± 1.9 23.1 ± 2.1
γ-glutamyl transpeptidase (IU/l) 37.1 ± 7.0 28.1 ± 4.4* 42.6 ± 7.1 40.7 ± 6.5
Alkali phosphatase (IU/l) 212.3 ± 10.9 205.5 ± 12.1 197.6 ± 11.4 199.4 ± 11.5
Blood urea nitrogen (mg/dl) 14.2 ± 0.7 13.8 ± 0.8 13.6 ± 0.9 13.3 ± 1.0
Creatinine (mg/dl) 0.7 ± 0.03 0.7 ± 0.03 0.7 ± 0.03 0.7 ± 0.03
Total cholesterol (mg/dl) 192.2 ± 7.0 183.9 ± 5.8 210.1 ± 8.3 199.8 ± 6.5
High density lipoprotein cholesterol (mg/dl) 58.3 ± 4.0 56.3 ± 4.0 63.1 ± 4.0 59.7 ± 3.9
Low density lipoprotein cholesterol (mg/dl) 116.3 ± 6.3 110.9 ± 4.9 128.2 ± 6.4 121.2 ± 4.6
Triglycerides (mg/dl) 99.8 ± 16.7 92.1 ± 11.6 144.2 ± 32.4 131.3 ± 19.7
Total protein (g/dl) 7.1 ± 0.1 7.0 ± 0.1* 7.1 ± 0.1 6.9 ± 0.1**
Albumin (g/dl) 4.4 ± 0.1 4.3 ± 0.1 4.4 ± 0.02 4.3 ± 0.1*
Albumin-globulin ratio 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.04 1.6 ± 0.04
Total bilirubin (mg/dl) 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
Lactate dehydrogenase (IU/l) 186.9 ± 5.2 176.1 ± 5.0* 193.9 ± 7.2 189.1 ± 8.9
Blood glucose (mg/dl) 91.4 ± 2.1 88.4 ± 1.9* 98.6 ± 3.1 92.7 ± 3.2**
HbA1c (%) 4.9 ± 0.1 4.9 ± 0.1 5.1 ± 0.2 5.0 ± 0.1
Uric acid (mg/dl) 5.0 ± 0.3 5.2 ± 0.3 5.4 ± 0.3 5.6 ± 0.4
Na+ (mEq/l) 141.8 ± 0.4 142.7 ± 0.4 142.3 ± 0.3 142.7 ± 0.5
K+ (mEq/l) 4.2 ± 0.1 4.2 ± 0.1 4.3 ± 0.1 4.3 ± 0.1
Cl− (mEq/l) 104.0 ± 0.4 105.1 ± 0.5** 103.9 ± 0.5 105.2 ± 0.5*
Ca2+ (mEq/l) 9.3 ± 0.1 9.3 ± 0.1 9.3 ± 0.1 9.3 ± 0.1
Mg2+ (mEq/l) 2.3 ± 0.04 2.4 ± 0.1 2.3 ± 0.04 2.3 ± 0.04
Urinalysis
Urine pH 6.3 ± 0.1 6.1 ± 0.1* 6.3 ± 0.1 6.3 ± 0.2
Glucosuria Not detected Not detected Not detected Not detected
Proteinuria Not detected Not detected Not detected Not detectedH. Tanaka et al.
J. Clin. Biochem. Nutr.
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containing vinegar and dried bonito without GABA; HR,
Heart rate; SBP, Systolic blood pressure; DBP, Diastolic
blood pressure.
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